Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs ENTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENTX Captures Overall Composite Edge (45.2 HOLD vs 39.0 SELL), While VIVS Leads 3–2 on Growth & Valuation Pillars
ENTX Overall Winner
6-Pillar Tally: VIVS 3 – 2 ENTX (1 Tie)
Matrix Metrics: VIVS 1 – 6 ENTX
As of Nov 19, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (45.2/100 HOLD vs. 39.0/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus ENTX at $3.28 (N/M Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. VIVS 39.0/100 SELL) and 0.86β · 54% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VIVS vs ENTX
VIVS
VivoSim Labs, Inc. Common Stock
$0.29
+142.92% 1D
Market Cap
$2.4M
TTM Revenue
$112,000
Forward P/E
N/M
Beta / 30D Vol
0.83β · 480% Vol
Unified Composite Score
39.0
SELL
Tech 5.0
Fund 47.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ENTX
Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
$3.28
+0.61% 1D
Market Cap
$567.7M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.86β · 54% Vol
Unified Composite Score
45.2
HOLD
Tech 25.0
Fund 51.0
Flow 68.0
Mom 60.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (VIVS 3 – 2 ENTX)
1. Valuation Multiples
VIVS
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
9.6x
N/M
2. Growth & Scale
VIVS
Revenue Growth (YoY)
-51.4%
-100.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$112,000
N/A
Market Cap
$2.4M
$567.7M
3. Profitability & Quality
ENTX
Gross Margin
N/A
N/A
Operating Margin
-10117.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-343.1%
-20.3%
4. Balance Sheet & Cash Flow
VIVS
Cash Generation (TTM)
-$11M EBITDA
-$16M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.4M Net Cash
$265M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTX
Options Structure Phase
BREAKDOWN
CONSOLIDATION
Current IV / %ile
N/A (N/A)
114.4% (33rd %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Neutral
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VIVS (1) vs ENTX (6)| Institutional Metric | VIVS | ENTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.4M | $567.7M | ENTX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -51.4% | -100.0% | VIVS | |
| Operating Margin (TTM) | -10117.0% | 0.0% | ENTX | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -343.1% | -20.3% | ENTX | |
| 52-Week Range Position | 5% ($0–$3) | 72% ($1–$4) | ENTX | |
| Beta / 30D Volatility | 0.83β · 480% Vol | 0.86β · 54% Vol | ENTX | |
| Unified Institutional Score | 39.0 / 100 (SELL) | 45.2 / 100 (HOLD) | ENTX | |
| Trailing 12M Revenue (USD) | $112,000 | N/A | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 9.6x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$11M EBITDA ($1.4M Net Cash) | -$16M ($265M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
VIVS +57.15 pp
3M Horizon
VIVS +0.37 pp
6M Horizon
ENTX +236.52 pp
1Y Horizon
ENTX +113.14 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VIVS Revenue | ENTX Revenue | VIVS Op. Margin | ENTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -882.4% | N/A | VIVS |
| FY2020 | $0M | $0M | -977.9% | -3059.7% | VIVS |
| FY2021 | N/A | $0M | N/A | -2139.6% | ENTX |
| FY2022 | $0M | $0M | -765.3% | -9714.2% | VIVS |
| FY2023 | $0M | N/A | -4792.2% | N/A | VIVS |
| FY2024 | $0M | $0M | -13840.4% | -5295.6% | ENTX |
| FY2025 | $0M | $0M | -8761.1% | -27450.0% | VIVS |
| FY2026 | $0M | N/A | -8768.7% | N/A | VIVS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VIVS
BREAKDOWN
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTX
CONSOLIDATION
Current IV
114.4%
IV Percentile
33rd %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VIVS Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VIVS vs ENTX Key Questions & Quantitative Answers
As of Nov 19, 2026, Entera Bio Ltd. (ENTX) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (45.2/100 HOLD vs. 39.0/100 SELL) after splitting the core matrix 6–1 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. VIVS trades at $0.29 (N/M Forward P/E, -10117.0% operating margin) versus ENTX at $3.28 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. VIVS 39.0/100 SELL) and 0.86β · 54% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VIVS leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), VIVS cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.
VIVS screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus ENTX (-20.3% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, ENTX carries 114.4% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.86β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTX vs VIVS · Reverse Pair
VIVS vs SSYS
· Sector Peer
VIVS vs PRLB
· Sector Peer
VIVS vs MTLS
· Sector Peer
ENTX vs IMMP
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma